ArticleFrontiers in oncology2025
APOL1 is a novel prognostic biomarker in thyroid cancer and correlates with immune infiltration.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although apolipoprotein 1 (APOL1) expression is upregulated in several types of cancers, including thyroid cancer (THCA), its specific role in THCA remains unclear. The aim of the present study was to analyze whether APOL1 could serve as a prognostic marker and predictor of immune cell infiltration (ICI) in THCA. Methods: APOL1 expression was assessed using TCGA and GTEx data, based on data from The Cancer Genome Atlas (TCGA). The diagnostic and prognostic value of APOL1 was assessed using Kaplan-Meier survival curves, receiver operating characteristic curves, Cox regression analysis and enrichment analysis in R. Kyoto Encyclopedia of Genes and Genomes and Gene Ontology were used to determine APOL1-related pathways. Furthermore, the correlation between APOL1 expression and ICI, as well as immune checkpoint genes, was investigated. Western blotting, cell counting Kit-8, wound healing assays, Transwell assays and 5-EdU were used to examine APOL1 expression and function in THCA. Results: Abnormally elevated expression of APOL1 was observed in THCA tissues based on the data from TCGA and GTEx. Functional biological analysis indicated a strong connection between APOL1 and immune signatures. Additionally, APOL1 expression showed a correlation with infiltration of various immune cell types, including macrophages, neutrophils, dendritic cells, T and B cells, Th1/2 cells, CD8 T cells and Tregs. The results of western blotting confirmed upregulated APOL1 expression in THCA tissues. Conclusions: In this study, we innovatively explored the potential association between APOL1 and the immune microenvironment, and demonstrated that APOL1 expression is upregulated in THCA tissues. Knockdown of APOL1 in THCA cells results in promoted proliferation and migration. Additionally, APOL1 may regulate ICI in the THCA microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.